Edition:
United Kingdom

Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

33.67CAD
15 Feb 2019
Change (% chg)

$-0.20 (-0.59%)
Prev Close
$33.87
Open
$34.14
Day's High
$34.52
Day's Low
$33.46
Volume
962,262
Avg. Vol
1,098,275
52-wk High
$36.52
52-wk Low
$18.62

Latest Key Developments (Source: Significant Developments)

Bausch Health Says FDA Is Close To Finalizing Its Review Of Duobrii; Expects Decision Shortly
Friday, 15 Feb 2019 

Feb 15 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH PROVIDES UPDATE FOR DUOBRII FILING.BAUSCH HEALTH COMPANIES INC - FDA IS CLOSE TO FINALIZING ITS REVIEW, AND WE EXPECT A DECISION FROM FDA SHORTLY..BAUSCH HEALTH - FDA WILL BE UNABLE TO MEET 15 FEB PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR NEW DRUG APPLICATION FOR DUOBRII.  Full Article

Bausch Health Companies To Reduce Debt By Additional $76 Million
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH TO REDUCE DEBT BY ADDITIONAL $76 MILLION, BRINGING TOTAL DEBT REPAYMENT IN QUARTER TO APPROXIMATELY $400 MILLION.BAUSCH HEALTH COMPANIES INC - AFTER $76 MILLION PAYMENT, COMPANY WILL HAVE ELIMINATED ALL MANDATORY AMORTIZATION FOR Q1 OF 2019.  Full Article

Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra Multifocal For Astigmatism Contact Lenses
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - Bausch Health Companies Inc ::BAUSCH + LOMB RECEIVES 510(K) CLEARANCE FROM FDA FOR BAUSCH + LOMB ULTRA® MULTIFOCAL FOR ASTIGMATISM CONTACT LENSES.BAUSCH + LOMB - ANTICIPATE BAUSCH + LOMB ULTRA® MULTIFOCAL FOR ASTIGMATISM WILL BE AVAILABLE TO EYE CARE PROFESSIONALS AND THEIR PATIENTS BY MID-2019.  Full Article

Bausch Health To Redeem $200 Mln Aggregate Principal Amount Of Outstanding 5.625% Senior Notes Due 2021
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ANNOUNCES REDEMPTION OF $200 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS OUTSTANDING 5.625% SENIOR NOTES DUE 2021.BAUSCH HEALTH COMPANIES INC - INTENDS TO USE CASH GENERATED FROM OPERATIONS TO FUND AGGREGATE REDEMPTION PRICE FOR NOTES.  Full Article

Bausch Health will expand contact lens manufacturing facilities in Rochester, NY and Waterford, Ireland
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH WILL EXPAND CONTACT LENS MANUFACTURING FACILITIES IN ROCHESTER, NY AND WATERFORD, IRELAND.BAUSCH HEALTH COMPANIES - EXPECTED THAT SITE EXPANSIONS WILL LEAD TO CREATION OF MORE THAN 200 JOBS OVER NEXT 4 YEARS.  Full Article

Bausch Health Announces U.S. Launch Of Bryhali
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ANNOUNCES U.S. LAUNCH OF BRYHALI™ (HALOBETASOL PROPIONATE) LOTION, 0.01%, FOR PLAQUE PSORIASIS IN ADULTS.BAUSCH HEALTH COMPANIES - EXPECTS TO START DISTRIBUTION OF BRYHALI LOTION TO U.S. WHOLESALE PHARMACEUTICAL DISTRIBUTORS LATER IN NOV..  Full Article

Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Bausch Health Companies Inc ::SALIX AND ALFASIGMA WILL INITIATE LATE-STAGE PROGRAM TO STUDY RIFAXIMIN IN PATIENTS WITH POSTOPERATIVE CROHN'S DISEASE.SALIX PHARMACEUTICALS SAYS ENTERED AMENDMENT TO EXISTING LICENSE AGREEMENT WITH ALFASIGMA S.P.A..SALIX PHARMACEUTICALS - CO, ALFASIGMA AGREED TO RESOLVE OUTSTANDING ARBITRATION REGARDING ANOTHER DEVELOPMENT PROJECT FOR FORMULATION OF RIFAXIMIN.  Full Article

Bausch Health's Bryhali Lotion Receives Tentative FDA Approval
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH'S BRYHALI™(HALOBETASOL PROPIONATE) LOTION, 0.01%, RECEIVES TENTATIVE FDA APPROVAL FOR PLAQUE PSORIASIS IN ADULTS.BAUSCH HEALTH COMPANIES INC - PLANS TO LAUNCH BRYHALI LOTION IN NOVEMBER 2018 UPON FINAL FDA APPROVAL.  Full Article

Dova, Salix Enter Exclusive Co-Promotion Agreement For Doptelet
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS & SALIX ENTER INTO EXCLUSIVE CO-PROMOTION AGREEMENT FOR DOPTELET® (AVATROMBOPAG).DOVA PHARMACEUTICALS - SALIX SALES FORCE WILL BEGIN SELLING DOPTELET IN MID-OCTOBER 2018.DOVA PHARMACEUTICALS - PURSUANT TO DEAL, CO WILL PAY SALIX A QTRLY FEE BASED ON NET SALES OF DOPTELET PRESCRIBED BY GASTROENTEROLOGISTS IN THE U.S..DOVA PHARMACEUTICALS - ENTERED INTO EXCLUSIVE AGREEMENT WITH SALIX PHARMACEUTICALS TO CO-PROMOTE DOVA'S DOPTELET IN UNITED STATES.  Full Article

Bausch Health Announces Xifaxan Intellectual Property Litigation Resolution
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ANNOUNCES RESOLUTION OF XIFAXAN® INTELLECTUAL PROPERTY LITIGATION.BAUSCH HEALTH - SALIX PARTIES TO GRANT ACTAVIS NON-EXCLUSIVE LICENSE EFFECTIVE JAN. 1, 2028 TO SALIX PARTIES' IP FOR XIFAXAN 550 MG TABLETS IN U.S..BAUSCH HEALTH COMPANIES INC - WILL NOT MAKE ANY FINANCIAL PAYMENTS OR OTHER TRANSFERS OF VALUE AS PART OF AGREEMENT.BAUSCH HEALTH COMPANIES INC - PARTIES HAVE AGREED TO DISMISS ALL LITIGATION RELATED TO XIFAXAN.  Full Article

CANADA STOCKS-TSX down as falling oil prices weigh on energy shares

Jan 2 Canada's main stock index dropped on Wednesday, the first trading session of the year, as energy shares fell on decline in oil prices pressured by rising production.